Delphinus Adds Dr. Elise Berman as New Medical Director to Growing Executive Team
June 18 2024 - 7:05AM
Business Wire
Dr. Berman’s breast imaging center leadership
will be instrumental in accelerating SoftVue’s adoption
trajectory
Delphinus Medical Technologies, a pioneering medical imaging
company that developed the SoftVue™ Breast Tomographic Ultrasound,
today announced that Elise Berman, M.D., has joined the company as
medical director.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240618500243/en/
Dr. Elise Berman, chief medical officer
of Delphinus Medical Technologies.(Photo: Business Wire)
Dr. Berman comes to Delphinus with a stellar track record that
includes establishing, growing and leading one of the Washington
D.C. area’s premier breast imaging practices. For 22 years at
Fairfax Radiological Consultants, Dr. Berman served in multiple
roles including medical director, breast imaging division chief,
director of breast MRI, and was a long-standing member of the
Executive Committee. As a medical leader of the group, Dr. Berman
implemented numerous programs to improve quality, patient
experience, and efficiency. She expanded breast imaging services
and oversaw significant increases in overall breast imaging volume,
added new breast imaging sites, and built the largest and most
highly regarded breast imaging team in the region. Outside of her
practice, Dr. Berman serves on the board of the Brem Foundation to
Defeat Breast Cancer and was part of the ACS NBCRT Risk Reduction,
Screening, and Early Detection Workgroup. In addition, Dr. Berman
was named “Top Doctor” and “Best of the Best” in her specialty by
her peers.
“There is no group more familiar with the struggles of women
with dense breasts than those who care for them, and Dr. Berman has
had intimate experience with this patient population throughout her
career,” said Delphinus CEO, Scott White. “We are excited to tap
her knowledge and insights to ensure we address not only the needs
of patients, but also providers at breast imaging centers with whom
we work.”
SoftVue, a tomographic breast ultrasound system for screening
dense breasts, is approved by the FDA and when paired with
mammography, has been shown to identify up to 20 percent more
cancers while also reducing false positives and decreasing
unnecessary call-backs and biopsies in women with dense breasts.
SoftVue provides a new annual screening solution for this
population and is the only ultrasound-based breast imaging system
that is approved for same day screening as mammography.
“I’ve spent most of my career understanding and developing
breast imaging programs, including centers of excellence, and have
become well-versed in how an imaging department functions and
operates at maximum capability and efficiency,” said Dr. Berman. “I
look forward to working with the team at Delphinus to advise and
lead the implementation of SoftVue, a groundbreaking breast imaging
system that addresses the needs of the large number of women in our
country who have dense breasts. I am thrilled to have the
opportunity to help this patient population, who have a higher risk
of breast cancer, and whose mammograms are harder to interpret for
cancer, because of their breast density.”
About Delphinus Medical Technologies, Inc.
Headquartered in Novi, Michigan, Delphinus Medical Technologies,
Inc., is a pioneering medical imaging company that developed
SoftVue™, featuring the first circular array transducer technology.
The patented technology is a 3D whole-breast ultrasound tomography
system that delivers no radiation, requires no compression, and
images the entire breast with a single scan. To learn more, visit
our website and follow us on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618500243/en/
Media Contact: Sam Choinski Pazanga Health Communications
schoinski@pazangahealth.com (860) 301-5058